Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) subsidiary Guangzhou Baiyunshan Tianxin Pharmaceutical received supplementary drug application approval from China's National Medical Products Administration for its cytidine diphosphate choline sodium injection.
The drug, also known as citicoline sodium, is indicated for acute traumatic brain injury and post-brain surgery-related conditions, according to a Thursday filing with the Shanghai bourse.